Company seeks more approval for clot blocker
from The Associated Press via USA Today
Johnson & Johnson said it has given the Food and Drug Administration additional data on its new anti-clotting drug, in a second attempt to get approval for more uses. Xarelto already is approved for three uses: for reducing risk of blood clots in people who've had knee replacement surgery or hip replacement surgery and for reducing stroke risk in people with a common irregular heart rhythm, atrial fibrillation, not caused by a heart valve problem.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063